Nasdaq Technology

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts ofte

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings oft

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings oft

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts ofte

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings oft

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings oft

ANI Pharmaceuticals (ANIP) reported $137.43 million in revenue for the quarter ended March 2024, representing a year-over-year increase of 28.7%. EPS of $1.21 for the same period compares to $1.17 a year ago.

For the quarter ended March 2024, DigitalOcean Holdings, Inc. (DOCN) reported revenue of $184.73 million, up 11.9% over the same period last year. EPS came in at $0.43, compared to $0.28 in the year-ago quarter.

Evolent Health (EVH) reported $639.65 million in revenue for the quarter ended March 2024, representing a year-over-year increase of 49.6%. EPS of $0.34 for the same period compares to $0.21 a year ago.

Deciphera Pharmaceuticals, Inc. (DCPH) reported $45 million in revenue for the quarter ended March 2024, representing a year-over-year increase of 34.5%. EPS of -$0.52 for the same period compares to -$0.60 a year ago.

Technology stocks were advancing pre-bell Friday with the Technology Select Sector SPDR Fund (XLK) up 0.3% and the SPDR S&P Semiconductor ETF (XSD) 0.8% higher recently.

Have you assessed how the international operations of The Manitowoc Company, Inc. (MTW) performed in the quarter ended March 2024? For this company, possessing an expansive global footprint, parsing the trends of international rev

Here are three stocks with buy rank and strong income characteristics for investors to consider today, May 10th:

It is never too late to invest in mutual funds for retirement. As such, if you plan to invest in some of the best funds, the Zacks Mutual Fund Rank can provide you with valuable guidance.

Investing in mutual funds for retirement is never too late. And the Zacks Mutual Fund Rank can be an excellent tool for investors looking to invest in the best funds.

Investing in mutual funds for retirement is never too late. And the Zacks Mutual Fund Rank can be an excellent tool for investors looking to invest in the best funds.

The cryptocurrency market experienced a lackluster April following a strong rally in the first quarter that led Bitcoin (BTC) to a new all-time high of $73,750.Over the past month (as of May 9, 2024), Bitcoin slumped about 11%. Th

Large Cap Growth fund seekers should consider taking a look at T. Rowe Price Growth Stock I (PRUFX). PRUFX has a Zacks Mutual Fund Rank of 2 (Buy), which is based on various forecasting factors like size, cost, and past performanc

Sector - Utilities fund seekers should consider taking a look at Franklin Utilities A1 (FKUTX). FKUTX has a Zacks Mutual Fund Rank of 2 (Buy), which is based on various forecasting factors like size, cost, and past performance.